Cargando…

TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy

Loss of p53 promotes vascular endothelial growth factor (VEGF)-A up-regulation and the angiogenic potential of cancer cells. We investigated TP53 somatic mutations in 110 primary gastric adenocarcinomas of two retrospective metastatic series including 48 patients treated with second-line Ramucirumab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graziano, Francesco, Fischer, Nicholas W., Bagaloni, Irene, Di Bartolomeo, Maria, Lonardi, Sara, Vincenzi, Bruno, Perrone, Giuseppe, Fornaro, Lorenzo, Ongaro, Elena, Aprile, Giuseppe, Bisonni, Renato, Prisciandaro, Michele, Malkin, David, Gariépy, Jean, Fassan, Matteo, Loupakis, Fotios, Sarti, Donatella, Del Prete, Michela, Catalano, Vincenzo, Alessandroni, Paolo, Magnani, Mauro, Ruzzo, Annamaria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465166/ https://www.ncbi.nlm.nih.gov/pubmed/32722340 http://dx.doi.org/10.3390/cancers12082049

Ejemplares similares

Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab
por: Ruzzo, Annamaria, et al.
Publicado: (2020)

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
por: Graziano, F, et al.
Publicado: (2008)

Ramucirumab: preclinical research and clinical development
por: Aprile, Giuseppe, et al.
Publicado: (2014)

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy
por: Catalano, V, et al.
Publicado: (2009)

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2011)

Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy
por: Ruzzo, Annamaria, et al.
Publicado: (2014)

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
por: Loupakis, Fotios, et al.
Publicado: (2013)

Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
por: Vincenzi, Bruno, et al.
Publicado: (2015)

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2020)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice
por: Angerilli, Valentina, et al.
Publicado: (2023)

Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
por: Pellino, Antonio, et al.
Publicado: (2019)

MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors
por: Angerilli, Valentina, et al.
Publicado: (2021)

KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
por: Chiari, Rita, et al.
Publicado: (2023)

Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy
por: Giampieri, Riccardo, et al.
Publicado: (2023)

Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management
por: Del Prete, Michela, et al.
Publicado: (2015)

Clinical Relevance of ABCB1, ABCG2, and ABCC2 Gene Polymorphisms in Chronic Myeloid Leukemia Patients Treated With Nilotinib
por: Loscocco, Federica, et al.
Publicado: (2021)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Metabolic Switch and Cytotoxic Effect of Metformin on Burkitt Lymphoma
por: Bagaloni, Irene, et al.
Publicado: (2021)

Tumor mutation burden: from comprehensive mutational screening to the clinic
por: Galuppini, Francesca, et al.
Publicado: (2019)

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status
por: Loupakis, Fotios, et al.
Publicado: (2019)

Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Cremolini, C, et al.
Publicado: (2010)

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
por: Di Bartolomeo, Maria, et al.
Publicado: (2019)

Clinical utility of ramucirumab in advanced gastric cancer
por: Chan, Matthew MK, et al.
Publicado: (2015)

The evolving strategies for the management of patients with metastatic gastric cancer: A narrative review and expert opinion
por: Cascinu, Stefano, et al.
Publicado: (2022)

LONG-NONCODING RNAs in gastroesophageal cancers
por: Fanelli, Giuseppe Nicolò, et al.
Publicado: (2018)

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
por: Cremolini, Chiara, et al.
Publicado: (2019)

The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective
por: Malapelle, Umberto, et al.
Publicado: (2023)

Ramucirumab: A New Therapy for Advanced Gastric Cancer
por: Oholendt, Andrea Landgraf, et al.
Publicado: (2015)

Population pharmacokinetic meta‐analysis of ramucirumab in cancer patients
por: O'Brien, Lisa, et al.
Publicado: (2017)

Gastric perforation related to concurrent use of nintedanib and ramucirumab
por: Takahashi, Saeko, et al.
Publicado: (2018)

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab
por: Gil-Delgado, Maria Angeles, et al.
Publicado: (2018)

Delayed Healing of Tooth Extraction Sockets with Ramucirumab Use
por: Iijima, Yosuke, et al.
Publicado: (2020)

Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab
por: Reig, Maria, et al.
Publicado: (2020)

Ramucirumab-Induced Hepatocellular Carcinoma Rupture and Gastrointestinal Perforation
por: Haider, Asim, et al.
Publicado: (2021)

Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases
por: Fassan, Matteo, et al.
Publicado: (2018)

Correction to: Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases
por: Fassan, Matteo, et al.
Publicado: (2019)

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
por: Catalano, V, et al.
Publicado: (2008)

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
por: Raimondi, Alessandra, et al.
Publicado: (2021)

PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target
por: Salvatore, Lisa, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ftbgu558qqs4nrum91mi05jml2